1468 related articles for article (PubMed ID: 30902670)
1. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis.
Li J; Zou B; Yeo YH; Feng Y; Xie X; Lee DH; Fujii H; Wu Y; Kam LY; Ji F; Li X; Chien N; Wei M; Ogawa E; Zhao C; Wu X; Stave CD; Henry L; Barnett S; Takahashi H; Furusyo N; Eguchi Y; Hsu YC; Lee TY; Ren W; Qin C; Jun DW; Toyoda H; Wong VW; Cheung R; Zhu Q; Nguyen MH
Lancet Gastroenterol Hepatol; 2019 May; 4(5):389-398. PubMed ID: 30902670
[TBL] [Abstract][Full Text] [Related]
2. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
[TBL] [Abstract][Full Text] [Related]
3. Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis.
Liu J; Tian Y; Fu X; Mu C; Yao M; Ni Y; Liu Y; Li Z
Chin Med J (Engl); 2022 Jul; 135(14):1682-1691. PubMed ID: 36070463
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.
Tan DJH; Ng CH; Lin SY; Pan XH; Tay P; Lim WH; Teng M; Syn N; Lim G; Yong JN; Quek J; Xiao J; Dan YY; Siddiqui MS; Sanyal AJ; Muthiah MD; Loomba R; Huang DQ
Lancet Oncol; 2022 Apr; 23(4):521-530. PubMed ID: 35255263
[TBL] [Abstract][Full Text] [Related]
5. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Younossi ZM; Koenig AB; Abdelatif D; Fazel Y; Henry L; Wymer M
Hepatology; 2016 Jul; 64(1):73-84. PubMed ID: 26707365
[TBL] [Abstract][Full Text] [Related]
6. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.
Riazi K; Azhari H; Charette JH; Underwood FE; King JA; Afshar EE; Swain MG; Congly SE; Kaplan GG; Shaheen AA
Lancet Gastroenterol Hepatol; 2022 Sep; 7(9):851-861. PubMed ID: 35798021
[TBL] [Abstract][Full Text] [Related]
7. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.
Quek J; Chan KE; Wong ZY; Tan C; Tan B; Lim WH; Tan DJH; Tang ASP; Tay P; Xiao J; Yong JN; Zeng RW; Chew NWS; Nah B; Kulkarni A; Siddiqui MS; Dan YY; Wong VW; Sanyal AJ; Noureddin M; Muthiah M; Ng CH
Lancet Gastroenterol Hepatol; 2023 Jan; 8(1):20-30. PubMed ID: 36400097
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology of non-alcoholic fatty liver disease in Asia.
Wong SW; Chan WK
Indian J Gastroenterol; 2020 Feb; 39(1):1-8. PubMed ID: 32152903
[TBL] [Abstract][Full Text] [Related]
9. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
[TBL] [Abstract][Full Text] [Related]
10. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
Bertot LC; Adams LA
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression.
Orci LA; Sanduzzi-Zamparelli M; Caballol B; Sapena V; Colucci N; Torres F; Bruix J; Reig M; Toso C
Clin Gastroenterol Hepatol; 2022 Feb; 20(2):283-292.e10. PubMed ID: 33965578
[TBL] [Abstract][Full Text] [Related]
12. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Thomas JA; Kendall BJ; Dalais C; Macdonald GA; Thrift AP
Eur J Cancer; 2022 Sep; 173():250-262. PubMed ID: 35944373
[TBL] [Abstract][Full Text] [Related]
13. The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040.
Ito T; Ishigami M; Zou B; Tanaka T; Takahashi H; Kurosaki M; Maeda M; Thin KN; Tanaka K; Takahashi Y; Itoh Y; Oniki K; Seko Y; Saruwatari J; Kawanaka M; Atsukawa M; Hyogo H; Ono M; Ogawa E; Barnett SD; Stave CD; Cheung RC; Fujishiro M; Eguchi Y; Toyoda H; Nguyen MH
Hepatol Int; 2021 Apr; 15(2):366-379. PubMed ID: 33580453
[TBL] [Abstract][Full Text] [Related]
14. Asian perspective on NAFLD-associated HCC.
Yip TC; Lee HW; Chan WK; Wong GL; Wong VW
J Hepatol; 2022 Mar; 76(3):726-734. PubMed ID: 34619251
[TBL] [Abstract][Full Text] [Related]
15. Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.
Pais R; Fartoux L; Goumard C; Scatton O; Wendum D; Rosmorduc O; Ratziu V
Aliment Pharmacol Ther; 2017 Nov; 46(9):856-863. PubMed ID: 28857208
[TBL] [Abstract][Full Text] [Related]
16. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009.
Younossi ZM; Otgonsuren M; Henry L; Venkatesan C; Mishra A; Erario M; Hunt S
Hepatology; 2015 Dec; 62(6):1723-30. PubMed ID: 26274335
[TBL] [Abstract][Full Text] [Related]
17. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease.
Degasperi E; Colombo M
Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):156-164. PubMed ID: 28404072
[TBL] [Abstract][Full Text] [Related]
18. Modelling NAFLD disease burden in four Asian regions-2019-2030.
Estes C; Chan HLY; Chien RN; Chuang WL; Fung J; Goh GB; Hu TH; Huang JF; Jang BK; Jun DW; Kao JH; Lee JW; Lin HC; Razavi-Shearer K; Seto WK; Wong GL; Wong VW; Razavi H
Aliment Pharmacol Ther; 2020 Apr; 51(8):801-811. PubMed ID: 32133676
[TBL] [Abstract][Full Text] [Related]
19. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis.
Wu Y; Zheng Q; Zou B; Yeo YH; Li X; Li J; Xie X; Feng Y; Stave CD; Zhu Q; Cheung R; Nguyen MH
Hepatol Int; 2020 Mar; 14(2):259-269. PubMed ID: 32130675
[TBL] [Abstract][Full Text] [Related]
20. NASH/Liver Fibrosis Prevalence and Incidence of Nonliver Comorbidities among People with NAFLD and Incidence of NAFLD by Metabolic Comorbidities: Lessons from South Korea.
Park J; Lee EY; Li J; Jun MJ; Yoon E; Ahn SB; Liu C; Yang H; Rui F; Zou B; Henry L; Lee DH; Jun DW; Cheung RC; Nguyen MH
Dig Dis; 2021; 39(6):634-645. PubMed ID: 33535211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
